| DB ID | MyCo_1431 |
| Title | Symptomatic Cryptococcal Antigenemia Presenting as Early Cryptococcal Meningitis With Negative Cerebral Spinal Fluid Analysis |
| Year | 2018 |
| PMID | 30256903 |
| Fungal Diseases involved | Cryptococcal meningitis |
| Associated Medical Condition | HIV-AIDS |
| Genus | Cryptococcus |
| Species | spp. |
| Organism | Cryptococcus spp. |
| Ethical Statement | Ethical approvals were obtained from the Uganda National Council of Science and Technology, Mulago Hospital Research and Ethics Committee, and University of Minnesota. |
| Site of Infection | None |
| Opportunistic invasive | Opportunistic |
| Sample type | Body fluid |
| Sample source | Blood |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | CrAg |
| Biomarker Full Name | CSF cryptococcal antigen |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | UK |
| Cohort | As part of screening for enrollment into the Adjunctive Sertraline for Treatment of HIV-Associated Cryptococcal Meningitis (ASTRO-CM) clinical trial, we prospectively consented 1201 HIV-infected adults who presented with suspected meningitis to evaluate for the etiology of meningitis at Mulago National Referral Hospital and Mbarara Regional Referral Hospital in Uganda. Study participants were HIV- infected adults (aged ≥18 years) with signs/symptoms of meningitis who provided written informed consent for lumbar puncture, diagnostic testing, and collection of research data. |
| Cohort No. | 1021 |
| Age Group | ≥18 |
| P Value | p=.91 |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Cryptococcal meningitis is the most common cause of meningitis in sub-Saharan Africa and accounts for 15% of human immunodeficiency virus (HIV)/AIDS-related deaths glob- ally. Cryptococcal antigenemia, which precedes the development of cryptococcal meningitis, has a prevalence of 8.8% among HIV-infected Ugandan adult outpatients with CD4 T-cell counts <100 cells/μL, and this prevalence is 2-fold greater among those hospitalized. Globally, the cryptococcal antigenemia prevalence is estimated at 6% in HIV-infected individuals with CD4 T-cell counts <100 cells/ μL. |
| Technique | Assay |
| Analysis Method | CrAg lateral flow assay |
| ELISA kits | None |
| Assay Data | CrAg lateral flow assay (LFA; Immy, Norman, Oklahoma) |
| Validation Techniques used | CrAg lateral flow assay |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
